Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636770 | 0.69 | — | — | |
| SCHEMBL17563127 | 0.69 | GPR119 (0.41) | KDM4ENQO1KCNH2GPR119 | |
| SCHEMBL16389765 | 0.69 | ALDH1A1 (0.36) | KDM4ENQO1KCNH2GPR119 | |
| SCHEMBL16881090 | 0.65 | — | — | |
| SCHEMBL23728101 | 0.65 | — | — | |
| SCHEMBL22276530 | 0.65 | — | — | |
| SCHEMBL4756829 | 0.65 | — | — | |
| SCHEMBL2999285 | 0.65 | — | — | |
| SCHEMBL509282 | 0.64 | TTR (0.42) | — | |
| SCHEMBL7426499 | 0.64 | NQO1 (0.53) | KDM4ENQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285807-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-2066674-B1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | claimed |
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | claimed |
| US-7625905-B2 | Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | claimed |
| WO-2009135788-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-12 | — | — | WO | claimed |
| US-20090281133-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-11-12 | — | — | US | claimed |
| EP-2066674-A1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-10 | — | — | EP | claimed |
| US-20090028818-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-01-29 | — | — | US | claimed |
| WO-2009013171-A2 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | claimed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | claimed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | claimed |
| WO-2008034731-A1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | claimed |
| EP-2285807-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| EP-2066674-B1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008034731-A1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281133-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | KDM4E 3124/4885NQO1 2943/4885KCNH2 2672/4885 |
| US-20080103125-A1 | Heterocylic antiviral compounds | CCR5, ACKR3, CXCR3 | KDM4E 4084/4885NQO1 1742/4885KCNH2 3419/4885 |
| US-20090028818-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | KDM4E 2769/4885NQO1 3042/4885KCNH2 2662/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | KDM4E 2675/4885NQO1 2308/4885KCNH2 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.